Mumbai, September 22 (Udaipur Kiran News): Shares of Anlon Healthcare Ltd surged on the BSE after the company announced the successful development of two new anti-malarial products — Artemether and Lumefantrine. The stock was trading at ₹142.93, up ₹8.50 or 6.32% from its previous close of ₹134.43.
The scrip opened at ₹136.70 and touched an intraday high of ₹147.80 and a low of ₹132.00. A total of 1,71,319 shares were traded during the session. On a weekly basis, the stock has moved between ₹147.80 and ₹106.30. The company’s market capitalisation currently stands at ₹769.53 crore.
The two new products are expected to be launched by November 2025, marking a significant addition to Anlon’s product portfolio as it seeks to meet evolving healthcare needs in both domestic and international markets.
Anlon Healthcare, a chemical manufacturing company, is engaged in producing pharmaceutical intermediates and Active Pharmaceutical Ingredients (APIs) that are supplied to clients across India and abroad.
Bhupendra Singh Chundawat is a seasoned technology journalist with over 22 years of experience in the media industry. He specializes in covering the global technology landscape, with a deep focus on manufacturing trends and the geopolitical impact on tech companies. Currently serving as the Editor at Udaipur Kiran, his insights are shaped by decades of hands-on reporting and editorial leadership in the fast-evolving world of technology.